Our technology platforms can lead to products that are easier to use for patients and caregivers while reducing costs for payors and the health care system.
The Xeris Solution for Conventional Formulation Limitations
Our proprietary
Non-aqueous formulation technology platforms are designed to address the limitations of aqueous formulations for certain drugs. The solutions and suspensions formulated using our technology have high stability and solubility.
HIGH STABILITY
HIGH SOLUBILITY
Our biocompatible non-aqueous injectable solutions and suspensions can be packaged for administration in various commercially available ways:
XeriSolTM can be used for SMALLER molecules
Our proprietary XeriSol™ and XeriJect™ non-aqueous formulation technology platforms are designed to address the limitations of aqueous formulations for certain drugs. The solutions and suspensions formulated using our technology have high stability and solubility.
How it works
- An aqueous formulation of a peptide or small molecule is created at an optimal, specific pH. This allows the peptide or small molecule to remain soluble at high concentrations in water.
- The solution is dried into a powder and reconstituted in an aprotic, polar (FDA-approved) liquid. The liquid prevents aggregation and fibrillation of the drug substance.
- When a ready-to-use XeriSol formulation is injected into a patient, it is effectively placed back into a water environment, where it behaves appropriately.
XeriJectTM enables SC and IM administration of LARGE molecules
The XeriJect formulation technology is best suited for drugs and biologics including large molecules such as proteins, monoclonal antibodies, and vaccines.
How it works
- Specialized drying or particle engineering techniques are employed to create powders.
- The powders are “wetted” with biocompatible diluents, creating ultra-concentrated, ready-to-use, thumb-pressure injectable visco-elastic suspensions formulations.
- The visco-elastic suspensions formulations are administered via IM or SC using commercially available, syringe, pens and pumps.
Using XeriJect, we have formulated suspensions with a protein concentration in excess of 450 mg/mL, far exceeding current aqueous formulation systems with maximum achievable protein concentrations of 50–250 mg/mL. Our technology platforms can lead to products that are easier to use for patients and caregivers while reducing costs for payors and the health care system.
Conventional Formulation Limitations
Injectable pharmaceuticals typically rely on liquid (water) to deliver drugs and biologics, but many drugs have low solubility in water and are not stable. There are a number of conventional approaches to addressing these barriers.